

Arden and Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and Lincolnshire Partnership Foundation Trust

Lincolnshire *PACE* Shorts

Summary of PACEF decisions from August 2016

For further details see *PACE Bulletin* Volume 10; Number 14 (October 2016)

SUMMARY OF PACEF DECISIONS: AUGUST UPDATE

Device, Dressing or Drug	Indication(s)	Traffic Light and <i>Joint Formulary</i> Status
Abiraterone 50mg tablets (<i>Zytiga</i>) (Janssen-Cilag Ltd)	For the treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.	RED Abiraterone (<i>Zytiga</i>) 250 mg tablets are already listed on the <i>Formulary</i> as RED for use in the treatment of castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen. The RED classification now extends to treating metastatic hormone-relapsed prostate cancer in people who have no symptoms or mild symptoms after androgen deprivation therapy has failed, and before chemotherapy is indicated.
Adalimumab injection (<i>Humira</i>) (AbbVie)	For the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult patients with an inadequate response to conventional systemic therapy.	RED Adalimumab injection (<i>Humira</i>) is already listed on the <i>Joint Formulary</i> as RED in line with licensed indications and NICE TAs. It is also licensed for the treatment of a number of conditions including: rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, Crohn's disease, paediatric Crohn's disease, ulcerative colitis and uveitis.
Beclometasone 50 microgram nasal spray (generic/ <i>Beconase</i>) (generic/GlaxoSmithKline)	For perennial and seasonal allergic rhinitis. Vasomotor rhinitis.	GREEN First line. Included in the <i>Lincolnshire Joint Formulary</i> . <i>Beconase Hayfever Relief for Adults</i> nasal spray 50mcg/dose is available to buy (GSL). <i>Beconase Hayfever</i> aqueous nasal spray 50mcg/dose is available over-the-counter from pharmacies (P).
Belimumab 120mg and 400mg solution for infusion (<i>Benlysta</i>) (GlaxoSmithKline)	For use as add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity despite standard therapy	RED Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> .
Budesonide 64 microgram nasal spray (generic/ <i>Rhinocort Aqua</i>) (generic/AstraZeneca)	For perennial and seasonal allergic rhinitis. Nasal polyps.	GREEN Second line. Included in the <i>Lincolnshire Joint Formulary</i> .

Calci-D chewable tablets (calcium carbonate 2.5g/vitamin D3 1000 i.u.) (Consilient Health)	For the prevention and treatment of calcium and vitamin D deficiency in the elderly. For use as an adjunct in osteoporosis.	GREEN Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> .
Canagliflozin 100mg and 300mg tablets (<i>Invokana</i>) (Janssen Cilag)	In adults with type 2 diabetes mellitus to improve glycaemic control as monotherapy or in combination with other glucose-lowering medicinal products including insulin.	Recommended as a treatment option when an SGLT2 inhibitor is indicated in combination with metformin; designation GREEN. Also approved by NICE for triple therapy in combination with metformin and a sulfonylurea or metformin and pioglitazone; designation GREEN. Also approved by NICE for monotherapy; designation GREEN. Included in the <i>Lincolnshire Joint Formulary</i> for use within NICE criteria.
Ceritinib 150mg capsules (<i>Zykadia</i>) (Novartis Pharmaceuticals UK Ltd)	For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.	RED Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> .
Co-danthrusate 50mg/60mg capsules (danthron/docusate)	For the treatment of constipation in the terminally ill.	GREEN usually following a recommendation from a palliative care specialist. Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> .
Dapagliflozin (<i>Forxiga</i>) 5mg and 10mg tablets	In adults with type 2 diabetes mellitus to improve glycaemic control as monotherapy or in combination with other glucose-lowering medicinal products including insulin.	Recommended as a treatment option when an SGLT2 inhibitor is indicated in combination with metformin; designation GREEN. Also approved by NICE for monotherapy; designation GREEN for this indication. Included in the <i>Lincolnshire Joint Formulary</i> for use within NICE criteria.
Empagliflozin (<i>Jardiance</i>) 10mg and 20mg tablets	In adults with type 2 diabetes mellitus to improve glycaemic control as monotherapy or in combination with other glucose-lowering medicinal products including insulin.	Recommended as a treatment option when an SGLT2 inhibitor is indicated in combination with metformin; designation GREEN. Also approved by NICE for triple therapy in combination with metformin and a sulfonylurea or metformin and pioglitazone; designation GREEN. Also approved by NICE for monotherapy; designation GREEN for this indication. Included in the <i>Lincolnshire Joint Formulary</i> for use within NICE criteria.
Evacal D3 chewable tablets (calcium carbonate 1.5g/vitamin D3 400i.u.) (Teva UK)	For the prevention and treatment of calcium and vitamin D deficiency in the elderly. For use as an adjunct in osteoporosis.	GREEN Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> .
Fluticasone furoate 27.5 microgram nasal spray (<i>Avamys</i>) (GlaxoSmithKline)	Allergic rhinitis	GREEN Third line. Included in the <i>Lincolnshire Joint Formulary</i> .
Fluticasone propionate/azelastine hydrochloride 50 microgram/137 microgram nasal spray (<i>Dymista</i>) (Meda)	For perennial and seasonal allergic rhinitis.	RED-RED Not included in the <i>Lincolnshire Joint Formulary</i>

Fluticasone propionate 50 microgram nasal spray (<i>Flixonase</i>) (GlaxoSmithKline)	For perennial and seasonal allergic rhinitis.	RED-RED Not included in the <i>Lincolnshire Joint Formulary</i> .
Trametinib 0.5mg and 2mg tablets (<i>Mekinist</i>) (Novartis Pharmaceuticals UK Ltd)	For use as monotherapy and in combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.	RED Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> . The NICE TA only covers use in combination with dabrafenib.
Voriconazole 1% eye drops (unlicensed special)	For corneal ulcers and fungal keratitis.	RED Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> .

RED-RED: This signifies that a product is **not recommended** for prescribing in **either** primary or secondary care. All new products are classified as RED-RED pending assessment by PACEF.

RED: This signifies that a product has been approved for use within secondary care, tertiary care or a primary care hosted specialist service only and **should not be routinely prescribed in primary care**. RED drugs may be used within ULHT or LPFT subject to approval for use within each Trust. ULHT and LPFT reserve the right to determine whether or not RED drugs will be used within their Trusts. RED classification does not automatically signify that a drug will be available within secondary/tertiary care.

AMBER: This signifies that a drug has been approved for use in primary care **subject to specialist initiation; a shared care guideline (SCG) may also be required**. The main purpose of the SCG will be to clearly define both specialist and GP responsibilities. Not all AMBER drugs that require SCGs are currently covered by formal documents; PACEF are working to rectify this.

GREEN: This signifies a product that is **approved for initiation in either primary or secondary care**.

What's new this month?

- For patients requiring treatment for perennial or seasonal allergic rhinitis always consider self-care as a first line option. Where prescribing is unavoidable, beclometasone 50 microgram nasal spray (generic/*Beconase*) should be prescribed first line. Fluticasone containing products should be restricted to a third line role. *Flixonase* nasal spray is prohibitively expensive and *Avamys* nasal spray should always be preferred (see page 4 of the bulletin).
- Following a review of new calcium and vitamin D preparations, first line preferred products are confirmed as: *Accrete D3 tablets*, *Adcal D3 Chewable tablets*, *Adcal D3 Caplets*, *Calceos Chewable tablets*, *Evacal D3 chewable tablets*, *Natecal D3 chewable tablets* (all twice daily) and *Calci-D chewable tablets* and *theiCal-D3 chewable tablets* (once daily) (see page 6 of the bulletin).
- NICE have now approved all three of the SGLT-2 inhibitors, canagliflozin, dapagliflozin and empagliflozin, for use as monotherapies in the treatment of type 2 diabetes (see page 10 of the bulletin).

This bulletin has been created specifically to convey details of decisions taken at the Prescribing and Clinical Effectiveness Forum (PACEF) to all stakeholders across the Lincolnshire Healthcare Community in both primary and secondary care. Back issues of the *PACE Bulletin* and *PACE Shorts* are available through the PACEF website (<http://lincolnshire-pacef.nhs.uk>); follow the commissioning link to PACEF. Electronic copies of the *PACE Bulletin* are circulated to a wide readership via email. If you are not currently on our distribution list and wish to receive regular copies of PACEF publications please contact Sandra France on sandra.france@ardengemcsu.nhs.uk.

Google searching can be a quick and effective way of finding back numbers of the *PACE Bulletin* relevant to a specific topic of interest. Searchers are advised to use the official version of the *Bulletin* available from the PACEF website rather than depend on a potentially unreliable draft or variant found through Google or an alternative search engine.

The *Lincolnshire Joint Formulary* is available on line and is fully searchable; it can be accessed at www.lincolnshirejointformulary.nhs.uk

THIS DOCUMENT IS INTENDED FOR USE BY NHS HEALTHCARE PROFESSIONALS ONLY AND CANNOT BE USED FOR COMMERCIAL OR MARKETING PURPOSES WITHOUT PERMISSION